Skip to main content
. 2018 Aug 1;25(8):674–689. doi: 10.5551/jat.40584

Table 4. Baseline demographic and clinical characteristics after propensity score matching.

Variable, n (%) Clopidogrel Prasugrel/Ticagrelor p
(n = 268) (n = 268)
Clinical presentation, n (%)
    STEMI, n (%) 137 (51.1) 166 (61.9) 0.01
    NSTEMI, n (%) 110 (41) 88 (32.8) 0.06
    Unstable angina, n (%) 20 (7.5) 13 (4.8) 0.28
Symptom, n (%)
    Killip ≥ 2 17 (6.4) 25 (9.3) 0.26
    Prior angina 68 (31.3) 94 (35.1) 0.44
Demographic, n (%)
    Age (year) 61 +/− 12 (31–89) 58 +/− 11 (31–88) 0.001
Sex
    Male 223 (83.2) 226 (84.3) 0.81
    Female 45 (16.8) 42 (15.7) 0.81
Risk factors/past medical history, n (%)
    Current smoking 135 (50.4) 135 (50.4) 1
    Hypertension 136 (50.8) 130 (48.5) 0.67
    Diabetes mellitus 61 (22.8) 66 (24.6) 0.33
    Obesity (BMI > 30 Kg/m2) 27 +/− 4.7 (18.5–44.8) 27 +/− 4.9 (17–54) 0.74
    Hyperlipidemia 135 (50.4) 121 (45.1) 0.26
    Family history of coronary artery disease (CAD) 52 (19.4) 67 (25) 0.15
    Prior STEMI 37 (13.9) 34 (12.7) 0.70
    Prior NSTEMI 14 (5.3) 21 (7.9) 0.29
    Prior angioplasty 46 (17.2) 40 (14.9) 0.48
    Prior CABG 9 (3.4) 7 (2.6) 0.80
    Prior Stroke 13 (4.8) 7 (2.6) 0.25
    Peripheral vascular disease 15 (5.6) 12 (4.5) 0.69
    Chronic Kidney Disease 9 (3.4) 12 (4.5) 0.66
Echographic characteristics,
    Left Ventricular Ejection Fraction (%) 55 +/− 11.3 (25–76) 55 +/− 10.7 (20–80) 0.30
Treatment, n (%)
    ACE inhibitors 245 (93.9) 247 (92.2) 0.50
    Beta–blockers 250 (95.4) 259 (96.6) 0.51
    Statins 254 (97) 262 (97.8) 0.60
    Oral anticoagulants (VKA antagonists) 32 (12.3) 0 (0.0) 0.0001
    GPIIbIIIa antagonist 88 (33.7) 83 (31) 0.52

Values are n +/− median (range) or n (%)

ACE = angiotensin-converting enzyme; BMI = body mass index; CABG = coronary artery bypass graft surgery; NSTEMI = Non ST segment elevation myocardial infarction; STEMI = ST segment elevation myocardial infarction